February 14, 2008 - The Center for Molecular Medicine (CMM) today announced the formation of a collaborative effort with its affiliates and QIAGEN NV to support research focused on discovering molecular biomarkers capable of helping diagnose breast cancer and other women’s health issues.
At the center of the collaboration is the CMM’s access to clinical samples, its molecular analysis capabilities as well as XenoBase, a software and database system developed at the Van Andel Research Institute. This specialized bio-informatic system is capable of analyzing a wide range of molecular and conventional clinical data to help researchers identify clinically actionable associations between diseases, biomarkers and treatments. XenoBase is the result of more than five years of work by Craig Webb, Ph.D. and Jeremy Miller, Ph.D., of the Van Andel Research Institute, a co-founding joint venture partner of CMM. Based on the result of QIAGEN’s initial research, the CMM may also provide laboratory-based genomics and proteomics services to assist QIAGEN in the development and validation of new molecular diagnostic tests.
For more information: www.cmmdx.org
October 30, 2026 
